Drug Trial Radar · NCT05372354
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Oct 18, 2022
Primary completion
Oct 12, 2026
Study completion Oct 12, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Conditions
- Multiple Myeloma
Interventions
CC-92480Drug
Specified dose on specified days
TazemetostatDrug
Specified dose on specified days
BMS-986158Drug
Specified dose on specified days
TrametinibDrug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: From first participant first visit until 28 days after the last participant discontinues study treatment, up to approximately 4 years
- Number of participants with Serious AEsTime frame: Up to approximately 4 years
- Number of participants with AEs meeting protocol-defined DLT criteriaTime frame: Up to approximately 4 years
- Number of participants with AEs leading to discontinuationTime frame: Up to approximately 4 years
- Number of deathsTime frame: Up to approximately 4 years
- Establish recommended Phase 2 dose (RP2D)Time frame: Up to approximately 2 years
- Establish dosing schedule of each combination for Part 2 Dose ExpansionTime frame: Up to approximately 2 years
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center
Birmingham, Alabama · Recruiting
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Alberta Health Services AHS - Foothills Medical Centre FMC
Calgary, Alberta, Canada · Recruiting
University of Alberta - Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
University Health Network UHN - Princess Margaret Hospital PMH
Toronto, Ontario, Canada · Recruiting
Oslo University Hospital
Oslo, Outside US and Canada, Norway · Recruiting
ICO - Hospital Germans Trias i Pujol
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario Marques de Valdecilla
Santander, Spain · Recruiting
NIHR UCLH Clinical Research Facility
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom · Recruiting
Local Institution - 0001
Leicester, Leicestershire, United Kingdom · Withdrawn
Local Institution - 0014
Liverpool, Merseyside, United Kingdom · Withdrawn
Churchill Hospital
Oxford, Oxfordshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.